Pharmacological properties of a novel PI3Kd inhibitor, DS-1515
K. Wakita (Tokyo, Japan), K. Koyama (Tokyo, Japan), S. Nakayama (Tokyo, Japan), Y. Nishiya (Tokyo, Japan), P. Chopra (Gurgaon, India), M. Seth (Gurgaon, India), P. Chabbra (Gurgaon, India), P. Srivastava (Gurgaon, India), A. Kumar (Gurgaon, India), M. Diwan (Gurgaon, India), K. Morimoto (Tokyo, Japan), M. Suzuki (Tokyo, Japan)
Source: International Congress 2018 – Basic pharmacology
Session: Basic pharmacology
Session type: Thematic Poster
Number: 1054
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Wakita (Tokyo, Japan), K. Koyama (Tokyo, Japan), S. Nakayama (Tokyo, Japan), Y. Nishiya (Tokyo, Japan), P. Chopra (Gurgaon, India), M. Seth (Gurgaon, India), P. Chabbra (Gurgaon, India), P. Srivastava (Gurgaon, India), A. Kumar (Gurgaon, India), M. Diwan (Gurgaon, India), K. Morimoto (Tokyo, Japan), M. Suzuki (Tokyo, Japan). Pharmacological properties of a novel PI3Kd inhibitor, DS-1515. 1054
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
In vitro pharmacological characterization of the potent, lung selective pan-JAK inhibitor TD-8236 Source: International Congress 2019 – Advances in asthma pharmacology Year: 2019
Pharmacological properties of novel LTC4 synthase inhibitor Source: International Congress 2017 – Novel mechanisms and treatments for asthma Year: 2017
In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014
ADME properties of a novel PI3Kd inhibitor, DS-1515, in preclinical studies Source: International Congress 2018 – Basic pharmacology Year: 2018
In-vitro evaluation of a new potent, selective pan-Janus kinase (JAK) inhibitor VR588 Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015
The bronchodilatory and anti-inflammatory effect of MT-810, a novel selective phosphodiesterase-4 (PDE4) inhibitor Source: Eur Respir J 2006; 28: Suppl. 50, 434s Year: 2006
In vitro pharmacological profile of SMP-028, a novel potent anti-inflammatory agentSource: Annual Congress 2010 - Models of airways disease Year: 2010
In vitro and in vivo pharmacological profile of RP6503, a novel dual PI3K Δ/gamma inhibitor, in pulmonary disease systemsSource: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013
Pre-clinical characterization of RP3128, a novel and potent CRAC channel inhibitor for the treatment of respiratory disorders Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013
NIK-626; a dual inhibitor of thromboxane synthase and 5-lipoxygenase, potential candidate as a novel anti-asthma compound Source: Eur Respir J 2001; 18: Suppl. 33, 264s Year: 2001
Late-breaking abstract: Pre-clinical characterization of RP3128, a novel and potent CRAC channel inhibitor for the treatment of respiratory disorders Source: Annual Congress 2011 - Late-Breaking Abstracts Session: New treatments and targets for airway disease Year: 2011
In vitro and in vivo anti-inflammatory activity of the novel PDE4 inhibitor roflumilastSource: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001
Pharmacological characterization of CHI25243, a novel potent inhaled inhibitor of neutrophil elastase Source: International Congress 2016 – Therapeutic horizons: novel targets and pharmacological models Year: 2016
Preclinical characterization of CPL-302-201, a novel, highly potent and selective PI3Kδ inhibitor for the treatment of inflammatory disorders Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Pharmacological profile and efficacy of GLPG1690, a novel ATX inhibitor for COPD treatment Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015
In vitro pharmacological characterization of a novel p38α (MAPK14) inhibitor designed for inhaled delivery Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016
Pharmacological profile of a novel, potent and oral TRPA1 antagonist. Characterization in a preclinical model of induced cough Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015
RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Pharmacological approach Source: Annual Congress 2006 - The critically ill patient: chronic obstructive lung disease Year: 2006
The pharmacological and safety profile of a novel selective phosphodiesterase-4(PDE4) inhibitor:- GRC- 3886 Source: Eur Respir J 2004; 24: Suppl. 48, 220s Year: 2004